Sugi Predict

Sugi Predict / Compounds / SCHEMBL18632452

SCHEMBL18632452

SCHEMBL18632452

Cc1cc2cc(Br)ccn2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.39
▸ MAPT P10636 5/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ GAA P10253 2/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KMT2A Q03164 1/20 0.33
▸ TSHR P16473 2/20 0.33
▸ KDM4E B2RXH2 5/20 0.32
▸ RAB9A P51151 4/20 0.32
▸ NPC1 O15118 3/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ TYK2 P29597 1/20 0.32
▸ PLAU P00749 1/20 0.31
▸ LMNA P02545 2/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PDE4B Q07343 1/20 0.31
▸ HCRTR1 O43613 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086583 0.79 KDM4E (0.36) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL21929803 0.77 AHR (0.37) AHRALDH1A1GAA
SCHEMBL15690214 0.76 ENPP3 (0.38) MAPTALDH1A1GAAKMT2AKDM4E
SCHEMBL22310396 0.76 AHR (0.39) AHR
SCHEMBL29027018 0.76 AHR (0.39) AHR
SCHEMBL29723754 0.76 AHR (0.36) AHR
SCHEMBL21488491 0.74 KDM4E (0.44) AHRMAPTALDH1A1TSHRKDM4E
SCHEMBL10038828 0.73 TP53 (0.37) MAPTALDH1A1GAAKMT2ARAB9A
SCHEMBL20602282 0.72 AHR (0.40) AHRMAPTALDH1A1NPSR1GAA
SCHEMBL19996370 0.72 PARP1 (0.35) AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658655-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-20 — — US disclosed
US-20250122192-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-04-17 — — US disclosed
WO-2024255765-A1 NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) 2024-12-19 — — WO disclosed
EP-4441042-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME Rgenta Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
CN-118748995-A 5-Pyrimidine carboxamide derivatives and methods of use thereof 亚根达医疗公司 2024-10-08 — — CN disclosed
WO-2024160278-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 — — US disclosed
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 — — US disclosed
US-11806346-B2 HTT modulators for treating Huntington's disease CHDI FOUNDATION, INC. (US) 2023-11-07 — — US disclosed
CN-116997548-A HTT modulators for the treatment of huntington's disease CHDI基金会股份有限公司 2023-11-03 — — CN disclosed
CN-116375683-A Diazole derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-07-04 — — CN disclosed
WO-2023102231-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
EP-4149937-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI Foundation, Inc. (US) 2023-03-22 — — EP disclosed
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. 2022-12-29 — — US disclosed
WO-2021231571-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. (US) 2021-11-18 — — WO disclosed
WO-2021231571-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE CHDI FOUNDATION, INC. (US) 2021-11-18 — — WO disclosed
EP-3080116-B1 PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-05-08 — — EP disclosed
US-9902720-B2 Pyrazolopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-02-27 — — US disclosed
US-20170081321-A1 Pyrazolopyridine Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2017-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122192-A1 5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND METHODS OF USING THE SAME RTCB, NSUN2, PRPF19 AHR 3404/4885MAPT 4668/4885ALDH1A1 861/4885
US-20170081321-A1 Pyrazolopyridine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, NFKBIA AHR 2995/4885MAPT 1632/4885ALDH1A1 1325/4885
US-20220409615-A1 HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 AHR 1424/4885MAPT 76/4885ALDH1A1 4119/4885
US-20250353858-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKK, DGKA AHR 2586/4885MAPT 4390/4885ALDH1A1 3815/4885
US-11806346-B2 HTT modulators for treating Huntington's disease HTT, HYPK, ATXN2 AHR 1424/4885MAPT 76/4885ALDH1A1 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.